ErikAllenImelMD
Endocrinology • Indianapolis, INLipid Metabolism, Osteoporosis & Bone Metabolism Medicine, Parathyroid, Pediatric Endocrinology
Professor, Medicine and Pediatrics, Indiana University School of Medicine
Dr. Imel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
550 University Blvd
Ste 2180
Indianapolis, IN 46202Phone+1 317-944-7718Fax+1 317-944-1289
Education & Training
Indiana University School of MedicineFellowship, Pediatric Endocrinology, 2003 - 2007
University of RochesterResidency, Internal Medicine/Pediatrics, 1999 - 2003
University of Cincinnati College of MedicineClass of 1999
Certifications & Licensure
IN State Medical License 2003 - 2025
NY State Medical License 2003 - 2005- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
- American Board of Pediatrics Pediatric Endocrinology
Clinical Trials
- Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH) Start of enrollment: 2014 Jul 02
- Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot Project. Start of enrollment: 2014 Aug 01
- CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis Start of enrollment: 2019 Dec 18
- Join now to see all
Publications & Presentations
PubMed
- 27 citationsDisparities in osteoporosis treatmentsZiyue Liu, J. Weaver, A. E. de Papp, Z. Li, Joel Martin
Osteoporosis International. 2016-02-01 - 13 citationsApproach to Hypophosphatemic Rickets.Sarah A Ackah, Erik A Imel
The Journal of Clinical Endocrinology and Metabolism. 2022-12-17 - 25 citationsGlobal guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia.Suzanne M Jan de Beur, Salvatore Minisola, Wei-Bo Xia, Bo Abrahamsen, Jean-Jacques Body
Journal of Internal Medicine. 2023-03-01
Journal Articles
- A Randomized, Double‐Blind, Placebo‐Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti‐FGF23 Antibody, in Adults with X‐Linked Hypophosphatemia: W...Thomas Weber, Mary D Ruppe, Anthony A Portale, Erik A Imel, Thomas O Carpenter, Karl L Insogna, Farzana Perwad, Pisit Pitukcheewanont, Journal of Bone and Mineral Research
Press Mentions
Burosumab Effects Persist Long-Term for Children with Rare Form of RicketsSeptember 16th, 2020
Burosumab Improves Symptom Relief in Genetic RicketsJuly 5th, 2019
Clinical Trial Improves Treatment of Genetic RicketsMay 18th, 2019- Join now to see all
Grant Support
- FGF23 In Pediatric Phosphate Physiology And X-Linked Hypophosphatemic Rickets.National Institute Of Arthritis And Musculoskeletal And Skin Diseases2009–2011
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
